547 related articles for article (PubMed ID: 10471543)
1. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of malignant from benign solitary pulmonary lesions using chest radiography, spiral CT and HRCT.
Seemann MD; Seemann O; Luboldt W; Bonél H; Sittek H; Dienemann H; Staebler A
Lung Cancer; 2000 Aug; 29(2):105-24. PubMed ID: 10963841
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
Lee JH; Chang JH
Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of morphological characteristics for the differentiation of benign from malignant solitary pulmonary lesions using HRCT.
Seemann MD; Staebler A; Beinert T; Dienemann H; Obst B; Matzko M; Pistitsch C; Reiser MF
Eur Radiol; 1999; 9(3):409-17. PubMed ID: 10087107
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
7. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
8. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer.
Bates J; Rutherford R; Divilly M; Finn J; Grimes H; O'Muircheartaigh I; Gilmartin JJ
Eur Respir J; 1997 Nov; 10(11):2535-8. PubMed ID: 9426091
[TBL] [Abstract][Full Text] [Related]
10. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
11. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
12. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
13. [The diagnostic value of FDG coincidence imaging combined with serum tumor marker assays for pulmonary lesions].
Yang JG; Li CL; Gong M; Zou LF
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):683-5. PubMed ID: 17274375
[TBL] [Abstract][Full Text] [Related]
14. Assessment of malignancy in pulmonary lesions: FDG dual-head coincidence gamma camera imaging in association with serum tumor marker measurement.
Bousson V; Moretti JL; Weinmann P; Safi N; Tamgac F; Groiselle C; de Beco V; Hillali Y; Valeyre D; Breau JL
J Nucl Med; 2000 Nov; 41(11):1801-7. PubMed ID: 11079486
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
[TBL] [Abstract][Full Text] [Related]
19. [CYFRA 21-1: a new marker of epidermoid cancer of the bronchi. Comparison with 3 other markers].
Pujol JL; Grenier J; Ray P; Gautier V; Aouta MD; Michel FB
Presse Med; 1993 Jun; 22(22):1039-42. PubMed ID: 7692432
[TBL] [Abstract][Full Text] [Related]
20. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]